Literature DB >> 10738525

Enzymatic characterization of four new mutations in the glucose-6 phosphatase (G6PC) gene which cause glycogen storage disease type 1a.

N Bruni1, F Rajas, S Montano, F Chevalier-Porst, I Maire, G Mithieux.   

Abstract

Glycogen storage disease type 1a (GSD1a) is caused by mutations in the gene of glucose-6 phosphatase (G6PC), encoding the last enzyme of gluconeogenesis and glycogenolysis. To study the effect of mutations previously identified, but not yet enzymatically characterized, in French GSD1a patients, we used an in vitro expression system of the human glucose-6 phosphatase (hGlc6Pase) cDNA. Wild type hGlc6Pase expressed in COS-7 cells exhibited kinetic features comparable to microsomal Glc6Pase from normal human liver and kidney. Four new mutations inducing aminoacid changes in the coding sequence, e.g. W77R, A124T, G184E and L211P, were inserted into the Glc6Pase cDNA by site-directed mutagenesis, and studied after transient expression in COS-7 cells. All four mutations totally abolished Glc6Pase activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10738525     DOI: 10.1046/j.1469-1809.1999.6320141.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  8 in total

Review 1.  Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.

Authors:  Janice Y Chou; Hyun Sik Jun; Brian C Mansfield
Journal:  Nat Rev Endocrinol       Date:  2010-10-26       Impact factor: 43.330

Review 2.  Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease.

Authors:  Janice Y Chou; Brian C Mansfield
Journal:  Hum Mutat       Date:  2008-07       Impact factor: 4.878

3.  Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy.

Authors:  Julie Clar; Blandine Gri; Julien Calderaro; Marie-Christine Birling; Yann Hérault; G Peter A Smit; Gilles Mithieux; Fabienne Rajas
Journal:  Kidney Int       Date:  2014-04-09       Impact factor: 10.612

4.  Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.

Authors:  Zollie A Yavarow; Hye-Ri Kang; Lauren R Waskowicz; Boon-Huat Bay; Sarah P Young; Paul M Yen; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2020-01-15       Impact factor: 6.150

Review 5.  Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia.

Authors:  Monika Gjorgjieva; Laure Monteillet; Julien Calderaro; Gilles Mithieux; Fabienne Rajas
Journal:  J Inherit Metab Dis       Date:  2018-06-04       Impact factor: 4.982

6.  mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease.

Authors:  Jingsong Cao; Minjung Choi; Eleonora Guadagnin; Maud Soty; Marine Silva; Vincent Verzieux; Edward Weisser; Arianna Markel; Jenny Zhuo; Shi Liang; Ling Yin; Andrea Frassetto; Anne-Renee Graham; Kristine Burke; Tatiana Ketova; Cosmin Mihai; Zach Zalinger; Becca Levy; Gilles Besin; Meredith Wolfrom; Barbara Tran; Christopher Tunkey; Erik Owen; Joe Sarkis; Athanasios Dousis; Vladimir Presnyak; Christopher Pepin; Wei Zheng; Lei Ci; Marjie Hard; Edward Miracco; Lisa Rice; Vi Nguyen; Mike Zimmer; Uma Rajarajacholan; Patrick F Finn; Gilles Mithieux; Fabienne Rajas; Paolo G V Martini; Paloma H Giangrande
Journal:  Nat Commun       Date:  2021-05-25       Impact factor: 14.919

7.  Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control.

Authors:  Fabian Peeks; Thomas A H Steunenberg; Foekje de Boer; M Estela Rubio-Gozalbo; Monique Williams; Rob Burghard; Fabienne Rajas; Maaike H Oosterveer; David A Weinstein; Terry G J Derks
Journal:  J Inherit Metab Dis       Date:  2017-04-10       Impact factor: 4.982

8.  G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a.

Authors:  Daniel S Roseman; Tayeba Khan; Fabienne Rajas; Lucy S Jun; Kirtika H Asrani; Cleo Isaacs; Jeremiah D Farelli; Romesh R Subramanian
Journal:  Mol Ther       Date:  2018-01-31       Impact factor: 11.454

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.